Diacure

Quick links to important sections

Diacure

Method of action: Antidiarrheal, Obstructive

Treatment option: Irritable Bowel Syndrome

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diacure

Property Description
Active Ingredient Loperamide hydrochloride
Form Capsules, Tablets, Oral Solution
Pharmacological Class Antidiarrheal agent
General Purpose Symptomatic relief of acute, non-specific diarrhea
Origin Synthetic (Phenylpiperidine derivative)

What Type of Medicine is Diacure?

Diacure is a commercially available medication containing the active ingredient Loperamide hydrochloride, which is fundamentally classified as an antidiarrheal agent. Chemically, it is a synthetic phenylpiperidine opioid derivative, confirming its origin as a manufactured compound, not a naturally sourced substance. The efficacy of Loperamide is clinically recognized for its ability to regulate bowel activity. This oral medication is commonly utilized as an Over-the-Counter (OTC) product, positioning it as an accessible remedy for general, self-limiting digestive issues. Its primary design and action are focused exclusively on the gut, avoiding effects on the central nervous system.


Composition and General Purpose

The medication is a single-ingredient product, with Loperamide hydrochloride as the sole therapeutic component. It is presented in several common dosage forms for oral use, including convenient capsules and various formulations of tablets and oral solution. The general purpose of Diacure is to provide effective symptomatic relief when the digestive system is disrupted. This relief is achieved by acting on the intestinal wall to moderate the excessive contractions that lead to fluid loss. Loperamide acts locally on the digestive tract to slow down rapid intestinal transit. This action helps the body reabsorb essential water and electrolytes, which is the fundamental mechanism for controlling loose stools.

Regulatory References

  1. EMA Medicines Search

What side effects are possible with Diacure?

Possible side effects and safety information

The safety profile of Diacure, containing Loperamide hydrochloride, is defined by regulatory documents based on classified adverse reactions and specific usage constraints. Adverse effects are grouped by frequency and the body systems affected, primarily involving the Gastrointestinal and Nervous Systems.


Frequency-Classified Effects

Side effects documented in official prescribing information are categorized by their likelihood:

  • Common (affecting up to 1 in 10 people): Constipation, Flatulence, Headache, Nausea, and Dizziness.
  • Uncommon (affecting up to 1 in 100 people): Abdominal pain, Abdominal discomfort, Vomiting, and Skin rash.

Serious Adverse Reactions and Safety Constraints

Official labeling describes rare but serious adverse reactions, which include Ileus (paralytic ileus), Toxic megacolon, and severe hypersensitivity reactions, such as Anaphylactic shock and serious bullous skin conditions. The most critical risk is associated with misuse, as doses higher than officially recommended have been linked to serious cardiac events (e.g., QT prolongation).

Population-Specific Constraints: The medicine is contraindicated for use in children under 2 years of age. Caution is required when used by individuals with severe hepatic impairment due to the potential for increased systemic exposure and subsequent nervous system effects. The medicine is also contraindicated in conditions where inhibiting bowel movement is detrimental, such as acute ulcerative colitis or infectious diarrhea characterized by high fever and blood in the stool.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Diacure (Loperamide hydrochloride) by detailing potential serious effects on the Central Nervous System (CNS) and the cardiovascular system.

Documented Manifestations

Overdose manifestations include signs of CNS depression, such as profound somnolence, stupor, and miosis (pinpoint pupils). Other documented physical signs are muscular hypertonia and severe gastrointestinal effects like paralytic ileus.

Severe and Life-Threatening Outcomes

The most critical concerns documented are the life-threatening outcomes affecting the heart. Overdose is explicitly associated with the risk of severe cardiovascular events, including QT interval prolongation, serious ventricular arrhythmias (such as Torsades de Pointes), and cardiac arrest. Overdose may also result in severe respiratory depression.

When to Seek Immediate Help

The regulatory instruction is to seek immediate medical attention and contact emergency services without delay upon any suspicion or sign of overdose. Emergency management requires immediate supportive treatment and continuous Electrocardiogram (ECG) monitoring to detect and manage potential arrhythmias.

Naloxone is designated as the specific antidote for Loperamide-induced CNS and respiratory depression. Regulatory information specifically notes that children are more susceptible to CNS effects following an overdose.

Therapeutic Uses of Diacure

What Diacure Treats: Main Uses and Benefits

Diacure is commonly used to help with symptomatic relief across multiple diarrhea-related presentations. It is primarily applied in clinical settings that involve acute, non-specific diarrhea, a condition marked by the sudden appearance of frequent, loose, or watery stools. The medication is also considered relevant when supportive symptom management is appropriate for chronic diarrhea associated with conditions like Inflammatory Bowel Disease (IBD) and is used to assist in the management of high output for patients with an ileostomy.

It helps address symptom clusters characterized by excessive bowel frequency and a lack of control over bowel urgency. Applied when groups of symptoms create noticeable functional strain, the key therapeutic benefit is providing support that helps ease the overall symptom burden. Diacure may assist with managing a more formed stool consistency, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Fluidity and Frequency
Primary Focus: Addressing symptoms related to heightened physiological activity associated with acute, disruptive episodes.
Core Symptom: Supports managing the excessive volume and watery consistency of stools.
Patient Benefit: Contributes to easing the overall symptom load and supports maintaining a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Diacure (Loperamide)

Regulatory agencies define strict population criteria for using Diacure, focusing on age, underlying medical conditions, and physiological status.

Eligibility Classifications

Classification Population/Condition Regulatory Status
Contraindicated Children under 2 years of age Prohibited
Contraindicated Acute dysentery (bloody stools, high fever) Prohibited
Contraindicated Acute ulcerative colitis Prohibited
Use with Caution Hepatic impairment/dysfunction Restricted
Not Recommended Pregnancy (especially first trimester) Use Limited
Not Recommended Breastfeeding Use Limited

Age and General Eligibility

Diacure is approved for use in adults and adolescents aged 12 years and over for acute, non-specific diarrhea. It is contraindicated in pediatric patients less than 2 years of age due to safety risks, and children aged 2 to 12 years should only use it under medical supervision. The medicine is contraindicated for any individual with a known hypersensitivity to the active ingredient.

Conditional Restrictions

Use is prohibited in conditions where slowing down intestinal movement is unsafe, such as infectious colitis and the risk of toxic megacolon. Patients with severe hepatic impairment are identified as requiring use with caution due to the risk of increased systemic exposure and potential CNS toxicity. Use is not recommended during pregnancy or breastfeeding, as safety in these populations has not been definitively established by regulatory bodies.

What should I know about interactions with other medicines?

Diacure (Loperamide hydrochloride) is associated with officially documented interaction patterns primarily concerning its metabolism and transport, as well as pharmacodynamic risk reinforcement. The regulatory profile is structured by prohibiting certain combinations and formally documenting changes in drug exposure when specific substances are co-administered.

Classification Documentation Point (Regulatory Basis)
Contraindicated Combinations Co-administration is formally restricted for all medicinal products and herbal products known to prolong the QT interval (e.g., Class IA and III antiarrhythmics, certain antibiotics), due to the risk of serious cardiac adverse events.
Pharmacokinetic Interactions Potent enzyme and transporter inhibitors are associated with significant increases in Loperamide's systemic exposure (AUC) and plasma concentration ( C max). The combination of Itraconazole ( CYP3A4 inhibitor) and Gemfibrozil ( CYP2C8 inhibitor) resulted in an up to 13-fold increase in Loperamide exposure. Other P-glycoprotein ( P-gp) inhibitors, such as Quinidine and Ritonavir, cause a 2- to 3-fold increase in Loperamide plasma levels.
Pharmacodynamic Risk Co-administration with drugs that inhibit peristalsis (e.g., other opioids, anticholinergics) is expected to potentiate Loperamide's effect, formally increasing the risk of serious gastrointestinal sequelae, including ileus or toxic megacolon.
Population Note Caution is advised in cases of Hepatic Impairment due to the potential for increased systemic exposure resulting from reduced first-pass metabolism.

Loperamide is also documented to reduce the exposure of the P-gp substrate Saquinavir. The regulatory documents mandate avoiding specific substance combinations and specify the quantifiable pharmacokinetic outcomes of co-administration with key enzyme and transporter inhibitors.

Mechanism of Action

Molecular Mechanism of Action

Diacure (Loperamide) operates by exerting dual, synergistic mechanisms restricted to the gastrointestinal tract. The core action involves Loperamide binding as an agonist to mu-opioid receptors located within the myenteric plexus of the intestinal wall . This molecular interaction suppresses the presynaptic release of excitatory neurotransmitters, such as Acetylcholine, which dampens signaling within the Enteric Nervous System. The resulting physiological consequence is a reduction in the rate and strength of propulsive peristalsis, leading to a prolonged intestinal transit time.

Simultaneously, the molecule influences fluid transport through an anti-secretory mechanism, partially via the inhibition of the intracellular protein Calmodulin. This reduces the active secretion of water and electrolytes from the intestinal lining into the gut lumen. This reduced secretion, combined with the prolonged transit time, increases the time available for the mucosa to passively reabsorb existing water and electrolytes.

Crucially, the mechanism is functionally restricted to the periphery because Loperamide is a highly efficient substrate for the P-glycoprotein (P-gp) efflux pump in the blood-brain barrier, which actively restricts the drug’s mu-opioid agonism almost entirely to the gut wall.

Dosage and Administration Information

Diacure, containing Loperamide hydrochloride, is approved for oral administration only, available in several formulations including capsules, tablets, and oral solution. The general usage principle is to administer the medicine based on the occurrence of unformed stools, defining it as a pro re nata (PRN) use pattern.


Official Dosing Regimens

The pattern of use varies depending on the specific indication and formulation. For acute diarrhea in adults, the standard regimen begins with an initial dose of 4 mg (two 2 mg units). This is followed by a 2 mg dose administered after each subsequent unformed stool. The maximum daily dose for severe prescription use is 16 mg, though non-prescription use is typically limited to 8 mg per day. For the management of chronic diarrhea, maintenance dosing is adjusted to achieve clinical control, often ranging from 4 mg to 8 mg daily in divided doses.


Duration and Population Guidance

Treatment for acute self-limiting episodes should not extend beyond 48 hours. Administration must be promptly discontinued if no improvement is observed within this timeframe, or if adverse signs like abdominal distension or constipation occur.

No dose adjustment is required for older adults or individuals with renal impairment. However, administration requires caution in patients with hepatic impairment due to altered metabolism. Pediatric dosing for children aged 2 to 12 is weight- and age-based, often utilizing the oral liquid formulation. Regardless of the form used, appropriate fluid and electrolyte replacement is an essential component of the overall treatment protocol, as the medicine does not substitute for hydration therapy.

Recent Clinical Evidence

Diacure: Recent Clinical Evidence

This section summarizes the findings from clinical research and trials concerning the compound Diacure.

Research on Biological Characteristics

Research has explored the biological characteristics of the compound. The first phase of research involved laboratory evaluations. These pre-clinical evaluations informed the starting hypotheses for subsequent human research.

Efficacy Data from Phase 3 Trials

Studies have explored whether the drug is associated with a change in symptoms across a patient population defined by specific inclusion criteria. These trials typically used a randomized, placebo-controlled design to assess the difference in outcome measures, such as change in symptomatic measures and quality of life scores, between the treatment and control groups.

Research has explored the drug's activity in participants with mild-to-moderate cases. The primary endpoints evaluated whether participants met pre-defined criteria for improvement at the 4-week and 12-week marks. The findings were mixed across various sub-groups, suggesting it is not yet clear whether a consistent effect is observed across all tested demographics.

Safety and Tolerability Data

Long-term data was collected in studies involving patients who continued treatment for up to 12 months. Researchers monitored the incidence of adverse events (AEs) and serious adverse events (SAEs) throughout the study duration.

Studies examined whether the drug was associated with changes in side effect incidence; research also compared its profile to other compounds. The most frequently reported adverse events in the trials included mild gastrointestinal discomfort and temporary headache.

Clinical trials defined specific exclusion criteria, such as people with pre-existing hepatic disease, and patients who were taking certain classes of medications, to manage risks within the controlled trial environment.

Dosing Regimen Studies

Research explored various starting and maintenance dosages in clinical trials. Clinical trials utilized specific dosage amounts and escalation rules as defined by the study protocols. Dosing adherence was also tracked and analyzed to understand its influence on measured outcomes.

Frequently Asked Questions (FAQ)

Common questions about Diacure (FAQ)

Q: Is Diacure classified as a long-term or a short-term treatment?

Diacure is intended for short-term use in acute diarrhea, where official guidance states treatment is typically limited to 48 hours. For the management of chronic diarrhea, regulatory information describes maintenance dosing which is adjusted under the supervision of a healthcare professional.

Q: What are the main expected benefits of taking Diacure?

The product's regulatory profile describes its function in slowing bowel movements and decreasing fluid loss. Official regulatory information describes the medicine’s function as providing symptomatic relief from diarrhea.

Q: Is Diacure meant to be used alone or in combination with other drugs?

Official product information notes that adequate fluid and electrolyte replacement is an important component of the overall treatment plan when using Diacure. Furthermore, the co-administration of Diacure with certain other medicines, particularly those affecting heart rhythm, is restricted.

Q: Are there any specific warnings about potential liver or kidney effects from Diacure?

Regulatory guidance advises caution for individuals with pre-existing hepatic impairment (liver problems) due to how the body metabolizes the drug. No dose adjustment is typically specified for patients with renal impairment (kidney problems).

Q: What type of gastrointestinal issues are associated with Diacure?

Regulatory documents that summarize adverse events include various gastrointestinal issues. These commonly reported effects include constipation, abdominal pain, abdominal discomfort, and nausea.

Q: How does Diacure interact with common dietary supplements like vitamins or herbal products?

Official documents describe that Diacure is contraindicated (not recommended for use) with herbal products known to prolong the QT interval (a measure of heart function). General interactions with common vitamins or other common supplements are typically not listed in the official product information.

Q: What types of prescription medicines are officially listed as having major interactions with Diacure?

Regulatory information documents interactions primarily with medicines that affect the drug's metabolism (e.g., certain enzyme inhibitors) or transport in the body. The combination of Diacure with any medicine known to prolong the QT interval may be restricted or contraindicated due to the potential risk of serious cardiac adverse events.

Q: Are there specific patient populations (e.g., people with existing heart issues) who should not use Diacure?

Patients with certain conditions are generally advised to avoid Diacure. Official contraindications include patients with known hypersensitivity to the drug, certain bacterial infections of the intestine, or any situation where inhibition of peristalsis (bowel movement) should be avoided, such as significant abdominal swelling.

Q: Does Diacure offer a cure for the condition or does it only help manage symptoms?

Official regulatory text describes Diacure as indicated for the control and symptomatic relief of diarrhea. It is not characterized as a curative treatment for the underlying cause of the condition.

Q: What are the most common side effects reported in official documents for Diacure?

According to official adverse event reporting summaries, the most frequently reported side effects are headache, dizziness, constipation, and nausea.

Q: How common are serious adverse events associated with Diacure?

Post-marketing surveillance reports have documented serious adverse events, including severe allergic reactions, toxic megacolon (a life-threatening bowel complication), and serious cardiac adverse events. These serious heart issues are most often linked to use at doses much higher than recommended or when the drug is misused.

Q: What are the signs of an allergic reaction to Diacure that patients should be aware of?

Patient information based on regulatory documents describes signs of a serious allergic reaction, which can include swelling of the face or throat, the development of a widespread rash, and difficulties with breathing.

Q: Is a change in weight a reported side effect of Diacure?

Regulatory summaries of adverse events typically do not list a change in body weight as a common or frequently reported side effect specifically associated with the product.

Q: Is fatigue or tiredness listed as a common side effect of Diacure?

Yes, official adverse event reporting indicates that fatigue (tiredness) and dizziness are side effects commonly reported by patients using Diacure.

Q: Does Diacure carry a Boxed Warning (Black Box Warning) in its regulatory labeling?

Yes, in the United States, the medicine's label contains a Boxed Warning. This warning highlights the potential for serious cardiac adverse reactions (heart problems) that can occur when the drug is used at doses significantly higher than recommended or when it is misused.

Q: What are the known long-term safety considerations for Diacure?

Regulatory information stresses that for acute, self-limiting diarrhea, treatment is typically limited to 48 hours. Caution is advised against prolonged administration, and any long-term use requires continuous medical supervision.

Q: What is the official guidance regarding driving or operating machinery while taking Diacure?

Official product documentation advises caution, as side effects such as dizziness, tiredness, or drowsiness may occur during treatment. If these effects are present, caution is advised regarding operating machinery or driving a vehicle.

Q: Is a metallic taste or mouth dryness reported in patients using Diacure?

Regulatory documents list dry mouth as a potential side effect, though it is often categorized as uncommon or rare. A metallic taste is typically not listed in the official adverse event summaries.

Q: Is it possible to experience headache as a side effect when starting Diacure?

Yes, regulatory adverse event reporting indicates that headache is listed as one of the most commonly reported side effects experienced by patients.

Q: How often are psychiatric or mood changes reported with Diacure use?

Regulatory summaries commonly report some effects on the nervous system, such as drowsiness and dizziness. Other psychiatric or mood changes are typically listed in the uncommon or rare categories of side effects.

Q: Are there official warnings about taking Diacure with alcohol?

Yes, official documents advise that the co-administration of alcohol may potentially reinforce the drug's effects on the central nervous system. Official documents recommend caution if consuming alcohol during treatment.

Q: Does Diacure interact with over-the-counter pain relievers such as acetaminophen or ibuprofen?

While specific common over-the-counter pain relievers are generally not singled out in the label, regulatory documents recommend consulting a healthcare provider about all concomitant medications, including any OTC medicines they are taking.

Q: Are there any known food or drink items that should be avoided when taking Diacure?

Official documents typically do not list specific foods that must be avoided. However, regulatory texts stress the importance of maintaining adequate fluid and electrolyte intake throughout the course of treatment.

Q: Is there a warning about combining Diacure with medications used for managing high blood pressure?

Regulatory documents require caution when combining Diacure with certain medicines that affect the QT interval of the heart. This category of medicines can include specific types of cardiac and blood pressure medications.

Q: What should be done if an interaction is suspected after taking Diacure with another medicine?

Patient information suggests immediately contacting a healthcare provider or seeking medical assistance. This applies if the user believes they are experiencing a suspected interaction or a serious side effect.

Q: How quickly do patients typically begin to notice the therapeutic effects of Diacure?

Regulatory pharmacokinetic data describes the rapid absorption of the drug into the system after it is taken orally. This data suggests symptomatic relief may be observed relatively soon after the first dose.

Q: What is the typical time frame expected to reach the full or maximum effect of Diacure?

Regulatory data provides the time it takes for the drug to reach its maximum concentration in the bloodstream, which occurs within a few hours. This information indirectly addresses the general time frame for the maximum therapeutic effect to be observed.

Q: How long does Diacure generally remain detectable in the body after a patient stops using it?

Regulatory documents provide the drug’s elimination half-life (the time it takes for half the dose to be cleared). This information defines the general time frame required for the medicine to be completely eliminated from the system.

Q: Is Diacure generally safe for women who are pregnant or planning to become pregnant?

Official regulatory text describes that use during pregnancy is typically avoided unless deemed essential by the prescriber. Furthermore, use while breastfeeding is generally not advised due to the potential for low levels of the drug to transfer to breast milk.

Q: What kind of research or clinical trials support the approval of Diacure?

The official regulatory documentation summarizes the clinical efficacy data that supports the drug’s approval. This information refers to controlled studies that demonstrated the drug’s symptomatic effect in treating both acute and chronic diarrhea.

How should Diacure be stored and disposed of?

How to Store and Dispose of Diacure?

The storage and disposal of Diacure (Loperamide hydrochloride) must adhere to the conditions specified in official regulatory labeling to ensure product integrity and safety.


Storage Requirements

Diacure must be stored at controlled room temperature, typically maintained between 20 C to 25 C (68 F to 77 F). It is essential to keep the medicine in its original container and ensure the container is tightly closed. The product must be protected from moisture and light and must not be refrigerated. Always store Diacure out of the sight and reach of children.


Disposal Instructions

Unused or expired Diacure should be discarded according to local regulatory requirements. Patients are advised to utilize an authorized drug take-back program if available, or to consult a pharmacist for guidance on proper disposal. The medicine must not be thrown away via wastewater (i.e., flushing down the toilet) or disposed of in general household rubbish.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diacure found in:

A-Z Index: